InMode (NASDAQ:INMD) Updates FY25 Earnings Guidance

InMode (NASDAQ:INMD) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $1.95-$1.99 for the period, compared to the consensus EPS estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.

InMode Price Performance

NASDAQ INMD traded up $0.67 on Tuesday, reaching $17.34. The company had a trading volume of 1,150,249 shares, compared to its average volume of 847,100. InMode has a 1 year low of $14.87 and a 1 year high of $26.80. The firm has a 50-day moving average of $17.48 and a 200-day moving average of $17.20. The firm has a market capitalization of $1.46 billion, a PE ratio of 9.36 and a beta of 2.13.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Tuesday. BTIG Research began coverage on InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Barclays reduced their price target on InMode from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 9th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $22.40.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.